Barrett食管内镜治疗安全性与有效性的真实世界证据
基于TriNetX电子健康记录数据库纳入2016至2020年Barrett食管伴异型增生或食管腺癌患者27556例,其中5295例接受Barrett食管内镜治疗(BET)。倾向性评分匹配后,BET与高级别异型增生(HGD)和食管腺癌(EAC)患者3年死亡率显著降低相关,食管狭窄是最常见不良事件(6.5%)。
要点
- BET与HGD患者3年死亡率降低相关(风险比0.59,95%CI 0.49-0.71)。
- BET与EAC患者3年死亡率降低相关(风险比0.53,95%CI 0.44-0.65)。
- BET后食管狭窄最常见,发生率为6.5%。
核心结论
- 真实世界大数据库证据显示,内镜治疗对Barrett食管患者安全有效,与3年死亡率显著降低相关,但6.5%的治疗患者发生食管狭窄。
研究设计与样本
- 基于电子健康记录数据库(TriNetX)的真实世界队列研究,纳入2016至2020年Barrett食管伴异型增生和食管腺癌患者。
- 共识别27556例Barrett食管伴异型增生患者,其中5295例接受Barrett食管内镜治疗(BET)。
- 采用1:1倾向性评分匹配控制混杂变量。
主要发现
- 倾向性评分匹配后,接受BET的HGD患者3年死亡率显著低于未接受BET的HGD患者(风险比0.59,95%CI 0.49-0.71,P<.001)。
- 倾向性评分匹配后,接受BET的EAC患者3年死亡率显著低于未接受BET的EAC患者(风险比0.53,95%CI 0.44-0.65,P<.001)。
- 接受BET的HGD患者与无Barrett食管/食管腺癌的GERD对照者3年死亡率无差异(风险比1.04,95%CI 0.84-1.27)。
- 接受BET与接受食管切除术的患者3年死亡率无差异:HGD(风险比0.67,95%CI 0.39-1.14,P=.14)和EAC(风险比0.73,95%CI 0.47-1.13,P=.14)。
- BET后最常见不良事件为食管狭窄(6.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Real-world data on the adverse events and the survival benefit of Barrett's endoscopic therapy (BET) are limited. The aim of this study was to examine the safety and effectiveness (survival benefit) of BET in patients with neoplastic Barrett's esophagus (BE). METHODS: An electronic health record-based database (TriNetX) was used to select patients with BE with dysplasia and esophageal adenocarcinoma (EAC) from 2016 to 2020. Primary outcome was 3-year mortality among patients with high-grade dysplasia (HGD) or EAC who underwent BET versus 2 comparison cohorts: patients with HGD or EAC who had not undergone BET and patients with GERD but no BE/EAC. Secondary outcome was adverse events (esophageal perforation, upper GI bleeding, chest pain, and esophageal stricture) after BET. To control for confounding variables, 1:1 propensity score matching was performed. RESULTS: We identified 27,556 patients with BE and dysplasia, of whom 5295 underwent BET. After propensity score matching, patients with HGD and EAC who underwent BET had significantly lower 3-year mortality (HGD risk ratio [RR], .59; 95% CI, .49-.71; EAC RR, .53; 95% CI, .44-.65) compared with corresponding cohorts who did not undergo BET (P < .001). There was no difference in median 3-year mortality between control subjects (GERD without BE/EAC) compared with patients with HGD (RR, 1.04; 95% CI, .84-1.27) who underwent BET. Finally, there was no difference in median 3-year mortality between patients who underwent BET compared with patients who underwent esophagectomy among both HGD (RR, .67; 95% CI, .39-1.14; P =.14) and EAC (RR, .73; 95% CI, .47-1.13; P = .14). Esophageal stricture was the most common adverse event (6.5%) after BET. CONCLUSIONS: Real-world, population-based evidence from this large database shows that endoscopic therapy is safe and effective for patients with BE. Endoscopic therapy is associated with a significantly lower 3-year mortality; however, it leads to esophageal strictures in 6.5% of treated patients.
引用
- Singh RR, Desai M, Bourke M, et al. Real-world evidence of safety and effectiveness of Barrett's endoscopic therapy. Gastrointest Endosc. 2023. PMID: 36914140. doi:10.1016/j.gie.2023.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。